Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period

NCT04007406 is registered in ClinicalTrials.gov with Damian Pharma AG as lead sponsor.

NCT NCT04007406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04007406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period
Lead sponsor
Damian Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2019
Completion date
May 2, 2022
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary aldosteronism